GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT) announces that the reverse stock split will become effective on June 16, 2025, at 12:01 a.m., Eastern Time. The Company’s common stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) under the existin ...

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has announced a proposed reverse stock split of its common stock at a ratio of 25-for-1, subject to Nasdaq approval, aimed at maintaining compliance with listing requirements and strengthening its capital structure [1][3]. Group 1: Reverse Stock Split Details - At the effective time of the reverse stock split, every 25 shares of the Company's common stock will be combined into 1 share, reducing the total number of shares from 26,210,037 to approximately 1,048,401 shares [2]. - The reverse stock split will also apply to common stock issuable upon the exercise of outstanding RSU grants and warrants, with no fractional shares issued; fractional entitlements will be rounded up to the next highest whole number [2]. Group 2: Company Overview - Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy [4]. - The Company's mission is to enhance the effectiveness of radiation therapy while minimizing side effects, aiming to increase cancer cure rates, prolong patient survival, and improve quality of life [4].

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has appointed George Scorsis as the Chairman of the Board of Directors, bringing extensive experience in leading companies in regulated industries to rapid growth [1][2]. Company Overview - Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on enhancing outcomes for cancer patients undergoing radiation therapy (RT) [4]. - The company's mission is to develop therapies that maximize the effectiveness of RT while minimizing side effects, aiming to increase cancer cure rates, prolong patient survival, and improve quality of life [4]. Leadership Experience - George Scorsis has over 25 years of experience in various industries, including alcohol, energy drinks, and biotech, with notable positions such as President at Mettrum Health Corp. and CEO of Liberty Health Sciences [2]. - He currently holds chairmanship roles at Entourage Health Corp. and AWAKN Life Sciences, both publicly traded [2]. Strategic Vision - Scorsis expressed his commitment to leveraging the company's radiation sensitizers to improve cancer treatment outcomes, particularly for glioblastoma patients, aiming to enhance cure rates and patient quality of life [3].